DGAP-News: Raptor Pharmaceutical Corp. to Present at the 30th Annual JP Morgan Healthcare Conference

Raptor Pharmaceutical Corp.

04.01.2012 22:39
—————————————————————————

Raptor Hosts Open Event to Discuss NASH Program and Upcoming Phase 2b Clinical
Trial

NOVATO, Calif., 2012-01-04 22:39 CET (GLOBE NEWSWIRE) —
Raptor Pharmaceutical Corp. (–Raptor– or the –Company–) (Nasdaq:RPTP) today
announced that Christopher M. Starr, Ph.D., Raptor–s Chief Executive Officer,
will present an overview of the Company at the 30th Annual JP Morgan Healthcare
Conference in San Francisco at the Westin St. Francis Hotel. Raptor–s
presentation will take place on Thursday, January 12, 2012, beginning at 12:00
p.m. PT.

A live audio webcast and 14-day archive of the presentation may be accessed via
the Investors and Media section of Raptor–s website www.raptorpharma.com.

In addition, Raptor is hosting an event providing an overview of its
non-alcoholic steatohepatitis (–NASH–) program on Tuesday, January 10, 2012 at
4:30pm PT in San Francisco during the JP Morgan Healthcare Conference. This
event will include Raptor–s management along with Jeffrey Schwimmer, M.D., an
expert in NASH. Dr. Schwimmer is Director of the Weight and Wellness Center at
Rady Children–s Hospital-San Diego and an investigator on Raptor–s planned
Phase 2b clinical trial in NASH in collaboration with the National Institute of
Diabetes and Digestive and Kidney Diseases, part of the National Institutes of
Health. The Company will provide a teleconference feed for those not attending
the conference. To attend or call into the event, please contact Lauren Glaser
at lglaser@troutgroup.com.

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. (Nasdaq:RPTP) (–Raptor–) seeks to research,
produce, and deliver medicines that improve life for patients with severe, rare
disorders. Raptor currently has product candidates in clinical development
designed to potentially treat nephropathic cystinosis, Non-alcoholic
Steatohepatitis (–NASH–), Huntington–s Disease (–HD–), aldehyde dehydrogenase
deficiency (–ALDH2–), and thrombotic disorder.

Raptor–s preclinical programs are based upon bioengineered novel drug
candidates and drug-targeting platforms derived from the human
receptor-associated protein and related proteins that are designed to target
cancer and infectious diseases.

For additional information, please visit www.raptorpharma.com.

The Raptor Pharmaceutical Corp. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7180

CONTACT: Trout Group (investors)
Lauren Glaser
(646) 378-2972
lglaser@troutgroup.com

EVC Group (media)
Janine McCargo
(646) 688-0425
jmccargo@evcgroup.com
News Source: NASDAQ OMX

04.01.2012 Dissemination of a Corporate News, transmitted by DGAP –
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP–s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

—————————————————————————

Language: English
Company: Raptor Pharmaceutical Corp.

United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US75382F1066
WKN:End of Announcement DGAP News-Service

—————————————————————————

  raptor-pharmaceutical-corp-to-present-at-the-30th-annual-jp-morgan-healthcare-conference